Pioneering surfactant therapy using bovine or porcine lung extracts, which consists of polar lipids and native SP-B and SP-C, has greatly improved the outcome of premature infants with neonatal respiratory distress syndrome (NRDS) (Polin & Carlo, 2014). The gene discussed is SFTPB; the disease is newborn respiratory distress syndrome.